加入收藏 欢迎光临Abbkine Scientific Co., Ltd官方网站全国服务热线:400-6800-830
登录 注册
中文

亚科因(Abbkine)—服务于细胞和蛋白研究全球用户

货号 产品名称 文献标题 IF 杂志名称
A23220 山羊抗兔IgG二抗, 绿色DyLight 488荧光标记 Programmable embedded bioprinting for one-step manufacturing of arterial models with customized contractile and metabolic functions. 14.900 Trends in Biotechnology 
A23220 山羊抗兔IgG二抗, 绿色DyLight 488荧光标记 Transcranial Magnetic Stimulation Alleviates Spatial Learning and Memory Impairment by Inhibiting the Expression of SARM1 in Rats with Cerebral Ischemia–Reperfusion Injury. 3.900 NeuroMolecular Medicine 
A23220 山羊抗兔IgG二抗, 绿色DyLight 488荧光标记 Decellularized Extracellular Matrix Scaffold Loaded with Regulatory T Cell-Conditioned Medium Induces M2 Macrophage Polarization. 9.600 Biomaterials research 
A23220 山羊抗兔IgG二抗, 绿色DyLight 488荧光标记 Selenium nanoparticles attenuate retinal pathological angiogenesis by disrupting cell cycle distribution. 3.900 Nanomedicine 
A23220 山羊抗兔IgG二抗, 绿色DyLight 488荧光标记 The impact of 12C6 heavy ion irradiation-induced cellular mutations on the replication of the foot-and-mouth disease virus and the role of Cbr3. 6.200 Cellular and Molecular Life Sciences 
A23220 山羊抗兔IgG二抗, 绿色DyLight 488荧光标记 GLUL mediates FOXO3 O-GlcNAcylation to regulate the osteogenic differentiation of BMSCs and senile osteoporosis. 14 Cell Death & Differentiation
A23220 山羊抗兔IgG二抗, 绿色DyLight 488荧光标记 p53 enhances elesclomol-Cu-induced cuproptosis in hepatocellular carcinoma via FDXR-mediated FDX1 upregulation. 3.300 Frontiers in Oncology 
A23220 山羊抗兔IgG二抗, 绿色DyLight 488荧光标记 CHK1 inhibition overcomes gemcitabine resistance in non-small cell lung cancer cell A549. 3 Molecular & Cellular Oncology 
A23220 山羊抗兔IgG二抗, 绿色DyLight 488荧光标记 Active spermatogenesis in YY supermale common carp makes it suitable for potential control of this invasive species. 4 Aquaculture 
A23220 山羊抗兔IgG二抗, 绿色DyLight 488荧光标记 CCDC134 enhances ovarian reserve function and angiogenesis by directly interacting with INHA in a mouse model of premature ovarian insufficiency. 8.100 Apoptosis 
意见反馈
在线咨询
扫码关注

微信公众号

返回顶部